Oxygenta Pharma

Why is Oxygenta Pharmaceutical Ltd falling/rising?

As of 01-Sep, Oxygenta Pharmaceutical Ltd's stock price is 55.99, down 0.16%. The stock has declined 7.24% over the last four days and 24.15% over the year, reflecting weak fundamentals and investor concerns despite a recent increase in trading volume.

As of 01-Sep, Oxygenta Pharmaceutical Ltd's stock price is currently at 55.99, reflecting a decrease of 0.09 (-0.16%). The stock has been experiencing a downward trend, having fallen for the last four consecutive days, resulting in a total decline of 7.24% during this period. Over the past week, the stock has underperformed the benchmark Sensex, which has decreased by only 0.92%, while Oxygenta's stock has dropped by 3.05%.<BR><BR>Despite a positive performance over the past month, where the stock rose by 11.85% compared to a decline of 1.47% in the Sensex, the overall yearly performance shows a significant decline of 24.15%, contrasting with the market's return of 2.32%. This underperformance is attributed to several negative factors, including a negative EBITDA of Rs. -7.99 crore and a negative book value of Rs 42.69 crore, indicating weak long-term fundamental strength.<BR><BR>While there has been an increase in investor participation, with delivery volume rising by 11.54% against the 5-day average, the stock's current trading conditions remain risky. The company has shown poor long-term growth, with net sales growing at an annual rate of only 13.83% and operating profit stagnant at 0% over the last five years. These factors contribute to the stock's current decline, reflecting investor concerns about its long-term viability and performance.

Who are in the management team of Oxygenta Pharma?

The management team of Oxygenta Pharma includes Sai Sudhakar Vankineni (Managing Director), D Vidya Sagar, Sangari Kondal Reddy, and Padmaja Surapureddy (Independent Directors), Muralidhar R (Director - Technical), Kanuganti Raghavender Rao (Executive Director), Sravani Reddy Gantla, Bharath Reddy Guntuku (Additional Directors), and Dolly Mandhan (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

The management team of Oxygenta Pharma includes the following members:<BR><BR>1. Sai Sudhakar Vankineni - Managing Director<BR>2. D Vidya Sagar - Independent Director<BR>3. Muralidhar R - Director (Technical)<BR>4. Sangari Kondal Reddy - Independent Director<BR>5. Padmaja Surapureddy - Independent Director<BR>6. Kanuganti Raghavender Rao - Executive Director<BR>7. Sravani Reddy Gantla - Additional Director<BR>8. Bharath Reddy Guntuku - Additional Director<BR>9. Dolly Mandhan - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Oxygenta Pharma do?

Oxygenta Pharmaceutical Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, previously known as S S Organics. As of June 2026, it reported net sales of 37 Cr and a net loss of 2 Cr, with a market cap of INR 214 Cr.

Overview: <BR>Oxygenta Pharmaceutical Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was initially incorporated as S S Organics Private Limited in 1990 and converted to a Public Limited Company in 1993, changing its name to S S Organics Limited. It was renamed Oxygenta Pharmaceutical Limited in FY 2021-22. The most recent quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 37 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: -2 Cr (Quarterly Results - Jun 2026) <BR>Market cap: INR 214 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.52 <BR>Return on Equity: 31.79% <BR>Price to Book: -5.01<BR><BR>Contact Details: <BR>Address: Survey No 252/1 Aroor Village, Sadasivapet Mandal Medak Telangana : 502291 <BR>Tel: 91-08455-250080/250280 <BR>Email: info@ssorganics.co.in <BR>Website: http://oxygentapharma.com

Who are the peers of the Oxygenta Pharma?

Oxygenta Pharma's peers include Kerala Ayurveda, Natural Capsules, Sanjiv.Parant., Coral Labs., Brooks Lab., CCME Global, Accretion Pha., and Sat Kartar Life. In terms of performance, Natural Capsules leads with an 8.63% 1-year return, while Kerala Ayurveda has the lowest at -63.87%, and Oxygenta Pharma's return is -27.69%.

Peers: The peers of Oxygenta Pharma are Kerala Ayurveda, Natural Capsules, Sanjiv.Parant., Coral Labs., Brooks Lab., CCME Global, Accretion Pha., and Sat Kartar Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanjiv.Parant. and Sat Kartar Life, while Good management risk is found at Accretion Pha. Below Average management risk is noted for Kerala Ayurveda, Natural Capsules, Coral Labs., Brooks Lab., and CCME Global, and the rest. Excellent growth is seen at Accretion Pha. and Sat Kartar Life, while Good growth is noted at Sanjiv.Parant. Below Average growth is present in Kerala Ayurveda, Natural Capsules, Coral Labs., Brooks Lab., and CCME Global, and the rest. Excellent capital structure is observed at Sanjiv.Parant. and Coral Labs., while Good capital structure is found at Accretion Pha. Below Average capital structure is noted for Kerala Ayurveda, Natural Capsules, Brooks Lab., and CCME Global, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Natural Capsules at 8.63%, while the peer with the lowest is Kerala Ayurveda at -63.87%. Oxygenta Pharma's 1-year return is -27.69%, which is better than Kerala Ayurveda but worse than Natural Capsules. Additionally, CCME Global has a negative six-month return.

How big is Oxygenta Pharma?

As of 31st August, Oxygenta Pharmaceutical Ltd has a market capitalization of 214.00 Cr and reported net sales of 134.84 Cr with a loss of 13.57 Cr over the latest four quarters.

As of 31st August, Oxygenta Pharmaceutical Ltd has a market capitalization of 214.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Oxygenta reported net sales of 134.84 Cr. However, the company experienced a loss of 13.57 Cr during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2026. Shareholder's funds stood at a loss of 42.69 Cr, while total assets were valued at 102.27 Cr.

Which are the latest news on Oxygenta Pharma?

Are Oxygenta Pharmaceutical Ltd latest results good or bad?

Oxygenta Pharmaceutical Ltd's latest results show strong revenue growth of 144.55% and improved operating margins, but the company still reported a net loss of ₹2.10 crores and has negative shareholder equity of ₹25.02 crores, indicating ongoing financial challenges. Overall, the results are mixed, suggesting a speculative investment.

Oxygenta Pharmaceutical Ltd's latest results present a mixed picture. On one hand, the company achieved a remarkable year-on-year revenue growth of 144.55%, with net sales reaching ₹37.00 crores. This indicates strong demand and a recovery from previous lows. Additionally, the operating margin improved to 1.49%, the highest in seven quarters, suggesting some operational efficiency gains.<BR><BR>However, the company also reported a net loss of ₹2.10 crores, which reflects a sequential decline of 23.53% from the previous quarter. The persistent negative profit after tax margin of -5.68% indicates that the company is still struggling to achieve profitability. Furthermore, Oxygenta has a negative shareholder equity of ₹25.02 crores, which raises concerns about its long-term viability.<BR><BR>Overall, while the revenue growth and improved operating margin are positive signs, the ongoing losses and negative equity position suggest that the results are not entirely good. The company remains in a precarious financial situation, making it a speculative investment at best.

Should I buy, sell or hold Oxygenta Pharmaceutical Ltd?

When is the next results date for Oxygenta Pharmaceutical Ltd?

The next results date for Oxygenta Pharmaceutical Ltd is 25 July 2026.

The next results date for Oxygenta Pharmaceutical Ltd is scheduled for 25 July 2026.

How has been the historical performance of Oxygenta Pharma?

Oxygenta Pharma experienced significant sales growth, reaching 109.30 Cr in March 2025, but faced rising expenditures leading to negative operating profit of -10.00 Cr and worsening profitability metrics. Total liabilities increased to 72.62 Cr, with negative shareholder's funds at -25.02 Cr, indicating ongoing financial distress despite a slight improvement in cash flow from operations.

Answer:<BR>The historical performance of Oxygenta Pharma shows significant fluctuations in its financial metrics over the years, with a notable increase in net sales in March 2025 reaching 109.30 Cr, up from 39.64 Cr in March 2024 and 30.99 Cr in March 2023. However, the company has faced challenges with total expenditure, which rose to 119.30 Cr in March 2025 from 49.34 Cr in March 2024, leading to an operating profit of -10.00 Cr in March 2025, slightly worse than -9.70 Cr in the previous year. The profit before tax also declined to -14.35 Cr in March 2025 from -13.87 Cr in March 2024, while the profit after tax was -10.30 Cr, worsening from -3.48 Cr in March 2024. The company's total liabilities increased to 72.62 Cr in March 2025 from 54.46 Cr in March 2024, with total debt at 62.23 Cr. Shareholder's funds remained negative at -25.02 Cr in March 2025, indicating ongoing financial distress. Cash flow from operating activities showed a slight improvement to 2.00 Cr in March 2025, compared to -13.00 Cr in March 2024, but cash flow from investing activities was negative at -11.00 Cr.<BR><BR>Breakdown:<BR>Oxygenta Pharma's financial trajectory reflects a complex mix of growth and challenges. The company's net sales surged to 109.30 Cr in March 2025, a significant increase from previous years, yet this growth was overshadowed by a sharp rise in total expenditure, which reached 119.30 Cr, resulting in an operating profit of -10.00 Cr. This trend continued with a profit before tax of -14.35 Cr and a profit after tax of -10.30 Cr, indicating deteriorating profitability. The total liabilities climbed to 72.62 Cr, with total debt at 62.23 Cr, while shareholder's funds remained negative at -25.02 Cr, highlighting ongoing financial difficulties. Despite a positive cash flow from operating activities of 2.00 Cr, the overall financial health of Oxygenta Pharma appears precarious as it navigates through these challenges.

Who are the top shareholders of the Oxygenta Pharma?

The top shareholders of Oxygenta Pharma are M V S Prasad Reddy with 25.56%, and Sravani Reddy Gantla as the highest public shareholder at 12.13%. Individual investors own 43.93%, with no pledged promoter holdings or foreign institutional investors involved.

The top shareholders of Oxygenta Pharma include M V S Prasad Reddy, who holds the largest stake at 25.56%. The highest public shareholder is Sravani Reddy Gantla, with a holding of 12.13%. Additionally, individual investors collectively own 43.93% of the company. There are no pledged promoter holdings, and the company does not have any foreign institutional investors (FIIs) involved.

Is Oxygenta Pharma overvalued or undervalued?

As of June 20, 2023, Oxygenta Pharma is considered overvalued and risky due to its negative financial ratios, including a PE ratio of -45.92 and a ROCE of -32.27%, despite a strong stock performance of 284.59% over the past year.

As of 20 June 2023, Oxygenta Pharma's valuation grade has moved from does not qualify to risky, indicating a significant shift in its financial standing. The company appears to be overvalued, given its negative PE ratio of -45.92, an EV to EBITDA ratio of -52.33, and a ROCE of -32.27%. These ratios suggest that the company's earnings and capital efficiency are under severe pressure.<BR><BR>In comparison to its peers, Oxygenta Pharma's valuation metrics are starkly unfavorable. For instance, Sun Pharmaceutical Industries Ltd. has a PE ratio of 35.25, while Cipla Ltd. boasts a PE of 22.99, both indicating a healthier financial position. Additionally, Oxygenta's PEG ratio stands at 0.00, which is significantly lower than the industry averages. Despite its recent stock performance, which has outpaced the Sensex with a 1-year return of 284.59% versus 7.60%, the underlying financial ratios suggest that the stock is not supported by fundamental value, reinforcing the conclusion that it is overvalued.

What is the technical trend for Oxygenta Pharma?

As of May 12, 2025, Oxygenta Pharma's trend has shifted to bullish, supported by positive weekly MACD and KST indicators, although caution is advised due to a bearish monthly RSI, despite a strong 1Y return of 274.62%.

As of 12 May 2025, the technical trend for Oxygenta Pharma has changed from mildly bullish to bullish. The weekly MACD and KST are both bullish, supporting the bullish stance. The daily moving averages also indicate a bullish trend. However, the monthly RSI is bearish, which suggests some caution. Overall, the strength of the bullish trend is reinforced by the performance metrics, with significant returns over various periods, particularly the 1Y return of 274.62%.

Has Oxygenta Pharma declared dividend?

No Dividend History Available